Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Kylynda C Bauer, Mohamed-Reda Benmebarek, Anuradha Budhu, Tim F Greten, Patrick Huang, Noemi Kedei, David E Kleiner, Firouzeh Korangy, Justin Lack, Elliot B Levy, Chi Ma, Christian T Mayer, Cecilia Monge, Yuta Myojin, Cihan Oguz, Francisco Rodriguez-Matos, Benjamin Ruf, Matthias Seifert, Marlaine Soliman, William Telford, Rajiv Trehan, Marina Villamor-Payà, Xin Wei Wang, Bradford J Wood, Changqing Xie

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: United States : Immunity , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 713654

Anti-vascular endothelial growth factor (VEGF) treatment has shown clinical activity together with immune checkpoint blockade (ICB), but the exact mechanism is not known. We show that VEGF blockade in combination with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) + anti-programmed death-ligand 1 (PD-L1) in cholangiocarcinoma (CCA) potentiated a multimodal mechanism dependent on B cell activating factor (BAFF), leading to a proinflammatory B cell response. It led to a BAFF- and interleukin (IL)-12-dependent expansion and rewiring of T regulatory cells (Tregs) toward an anti-tumor T helper-1 (Th-1)-like fragile state. We translated this approach to the clinic and observed immunological changes characterized by Treg cell expansion and rewiring toward fragile and unstable states. We explored the effect of VEGF receptor 2 (VEGFR2) signaling on Treg cell transcriptional programming and established a mouse model ablating VEGFR2 expression on Treg cells. This study reveals the immunological interplay resulting from targeting VEGF together with CTLA-4 and PD-L1 blockade.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH